Fertilisation

GrassRoots Turf: Lawn Care Company Expands Service Area in the Southeast

Retrieved on:

Dienstag, Mai 7, 2024

Insecticide, Grassroots, Weed control, Health, Heart, Aeration, The Mosquito Control EP, Environment, Tree, Malnutrition, Family, Oxygen, Soil, Beauty, Fertilisation, Control

GrassRoots Turf, a premier lawn care service franchise, is excited to announce its expansion into Louisiana and Alabama, further extending its reach in the Southeast.

Key Points:

GrassRoots Turf, a premier lawn care service franchise, is excited to announce its expansion into Louisiana and Alabama, further extending its reach in the Southeast.
Already operating successful franchises in Mississippi, Georgia, South Carolina, and North Carolina, GrassRoots Turf is known for its cost-effective, reliable lawn care solutions.
GrassRoots Turf is the only lawn care company in the Southeast offering video-recorded treatments with body cams.
Tree and Shrub Care: The top lawn care service company’s tree and shrub care program is personalized to accommodate the different types of shrubs and trees in a landscape.

In Vitro Fertilization Market Projected to Reach US$ 1,940.8 Million Valuation by 2034: Future Market Insights, Inc.

Retrieved on:

Dienstag, April 30, 2024

NEWARK, Del., April 30, 2024 /PRNewswire/ -- The in vitro fertilization market is on its way to perceive a surge in valuation, from US$ 1.50 billion in 2024 up to US$ 4.80 billion by 2034. FMI report indicates a healthy CAGR of 12.30% between 2024 and 2034, reckoning an influential IVF market growth.

Key Points:

The breath analyzers market is poised for steady growth, with a projected CAGR of 4.9% from 2024 to 2034.
By 2034, the market is expected to reach a valuation of US$ 1,154.3 million, reflecting significant expansion.
The in vitro diagnostics market is poised for steady growth, with a projected CAGR of 4.8% during the forecast period.
Sales of donor egg IVF are projected to reach US$ 7,159.50 million by 2034, with a robust CAGR of 7.90% between 2024 and 2034.

Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence

Retrieved on:

Mittwoch, April 17, 2024

Cytogenetics, Pregnancy, NMPA, OGM, Partnership, OEM, Doctor of Philosophy, Research, Artificial intelligence, Karyotype, Fertilisation, Genomics, Bone marrow, SVS, SAN, Medical device

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.

Key Points:

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.
Diagens has received Class I registration and approval for Bionano’s OGM reagents from China's NMPA and will register the Saphyr™ instrument with NMPA for clinical use in reproductive health.
“As a pioneer in AI chromosome karyotype analysis, we are very happy to establish a partnership with Bionano and to jointly explore the reproductive health market.
Diagens offers cutting-edge AI technology to help our customers to achieve a better overall success rate of in vitro fertilization.

Survey Reveals Women Trying to Get Pregnant Report Loneliness and Self-Blame

Retrieved on:

Donnerstag, Mai 2, 2024

A new survey commissioned by First Response™ in collaboration with RESOLVE: The National Infertility Association shows that women report feeling lonely, blame themselves and find misinformation as they are trying to get pregnant.

Key Points:

A new survey commissioned by First Response™ in collaboration with RESOLVE: The National Infertility Association shows that women report feeling lonely, blame themselves and find misinformation as they are trying to get pregnant.
More than two-thirds of women trying to conceive (68%) are worried about their ability to become pregnant and one-third were concerned that not being able to get pregnant would be their fault (32%).
Almost 2 in 5 women who are trying (38%) wish they knew how much conflicting information there was before they began attempting to get pregnant.
93% of women believe at least three misconceptions about trying to get pregnant when given a knowledge test about common facts regarding pregnancy.

Asia-Pacific Smart Vineyard and Orchard Equipment Industry Research 2023-2024 & 2028: Precision Viticulture Spurs Demand, IoT Sensors and Drones Revolutionize Vineyard and Orchard Management - ResearchAndMarkets.com

Retrieved on:

Mittwoch, Mai 1, 2024

Agriculture, Natural Resources, Internet, Horticulture, Internet of things, Country, Partnership, Farmer, Benchmarking, Soil, Fertilisation, Forestry, Viticulture

The rising need for effective and sustainable agricultural methods is expected to drive the expansion of the smart vineyard and orchard equipment market globally, particularly in the APAC region.

Key Points:

The rising need for effective and sustainable agricultural methods is expected to drive the expansion of the smart vineyard and orchard equipment market globally, particularly in the APAC region.
The smart vineyard and orchard equipment market in Asia-Pacific (APAC) is expected to grow significantly due to a number of factors.
With the growing emphasis on agricultural productivity, sustainability, and precision farming practices, there is a greater need for novel solutions to optimize vineyard and orchard management procedures.
The APAC smart vineyard and orchard equipment market includes a diverse variety of technologies and devices that aim to improve operational efficiency, reduce resource waste, and increase crop yields.

Talkspace Launches Behavioral Health Consortium of Specialized Care and Treatment Programs, Expanding In-Network Offerings for Members

Retrieved on:

Montag, April 29, 2024

Today, Talkspace , a leading online behavioral health company, announced the launch of its Behavioral Health Consortium, a curated network of specialty providers featuring Charlie Health , Ria Health , Bicycle Health , and more.

Key Points:

Today, Talkspace , a leading online behavioral health company, announced the launch of its Behavioral Health Consortium, a curated network of specialty providers featuring Charlie Health , Ria Health , Bicycle Health , and more.
This consortium enables Talkspace clinicians to refer insured members to like-minded, in-network, clinically-vetted specialty care providers who provide a higher level of care for higher acuity needs such as treatment for alcoholism, substance use, and eating disorders.
As one of the largest in-network digital mental healthcare providers, covering more than 130 million lives, Talkspace is helping patients stay in-network and enhancing access to comprehensive, whole person care.
“With the introduction of this consortium, we are better enabling our members to stay in-network for their specialty care needs, all within their Talkspace member experience.”
“At Talkspace, we recognize that some members may require a higher level of care or specialized treatment programs,” said Nikole Benders-Hadi, M.D., Chief Medical Officer at Talkspace.

CCRM FERTILITY ANNOUNCES THE LAUNCH OF LINKEDIN BADGE FOR EMPLOYERS TO DECLARE COMMITMENT TO FERTILITY BENEFITS

Retrieved on:

Montag, April 22, 2024

Religion, Fertility, NIAW, Human, The Knot Worldwide, Fertilisation, Partnership, Workplace, Research, Science, Family, Database, Organization, Birth control

LONE TREE, Colo., April 22, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, has partnered with Rescripted, the leading global media platform for holistic women's health, to launch a first-of-its-kind #FertilityCovered badge that will allow organizations to visually display their commitment to fertility benefits to current and prospective employees. The launch coincides with National Infertility Awareness Week (NIAW), April 21 - 27, 2024, which shines a light on the millions of Americans who face barriers in starting a family.

Key Points:

"Although fertility treatment can help many start or grow families, it is a time consuming and expensive undertaking, creating real obstacles for most Americans," said Robyn Mermelstein, Chief Marketing Officer for CCRM Fertility.
The #FertilityCovered badge is a first-of-its-kind visual representation for organizations to highlight their benefits, while also giving prospective employees the ability to search for positions that offer the badge.
Through this webpage, job seekers can find comprehensive information on fertility benefits, the significance of fertility coverage, how to advocate for benefits in the workplace, and more.
For additional information on the #FertilityCovered badge and to learn how to obtain the badge, please reach out to CCRM Fertility at [email protected] .

Rachio Marks Earth Day With 200 Billion Gallons of Water Saved Through Smart Yard Technology

Retrieved on:

Montag, April 22, 2024

Alexa, Weather, Environmental health, Health, Software, Water, Earth Day, Google Nest (smart speakers), Soil, Beauty, Fertilisation, Gardening

DENVER, April 22, 2024 /PRNewswire/ -- Rachio, the leading smart yard brand, is celebrating Earth Day with over 200 billion gallons of water saved through its innovative smart-watering technologies, working toward its goal of saving three trillion gallons by 2030. In honor of Earth Month, Rachio is encouraging communities to Connect Outside in healthier, eco-conscious ways that promote positive outdoor lifestyles and give back to the planet. From Rachio's water-saving smart sprinkler controllers and hose timers to partner products that prioritize human and environmental health, Rachio offers a holistic approach to outdoor living.

Key Points:

"This milestone of saving over 200 billion gallons of water reflects the effectiveness of our technology and our users' dedication to sustainability," said Kim Sentovich, Rachio CEO.
Rachio is most widely known for its water-saving smart watering devices, including the award-winning Rachio 3 Smart Sprinkler Controller and Smart Hose Timer .
These controllers allow users to manage yard watering directly through the free Rachio App, leveraging cutting-edge technology to optimize water usage.
Now through April 27th, Rachio is offering 20% off the Rachio 3 Smart Sprinkler Controller and Smart Hose Timer at Rachio.com.

Op-Ed: When Maternal Health Goes Wrong

Retrieved on:

Dienstag, April 16, 2024

WASHINGTON, April 16, 2024 /PRNewswire/ -- The best day of your life shouldn't be the most fearful. Women like me, Abby Phillips, Elain Welteroth, and others know what it means to manifest the life we've always dreamed of. But when it comes to being a mom, income doesn't matter. For Black and Brown women, our greatest dream can often be our worst nightmare because, regardless of our station, when it comes to healthy births for mothers and infants, the statistics are staggering: Black women are three times as likely to die from pregnancy-related causes as are White women.

Key Points:

You see, for me and many other Black women, maternal health and pregnancy are bittersweet.
For Black women, whether they are from the inner city or highly educated with high net worths, maternal health is the great equalizer beyond income.
Organizations such as Health and Human Services, the Center for Disease Control, and the National Institute of Health, Health Resources, and Services Administration have much work to do.
Continued investment in maternal health, addressing inequalities, and ensuring that all women have resources are easy fixes.

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Retrieved on:

Mittwoch, März 20, 2024

Infertility, TMSC, Pregnancy rate, IVF, IUI, Pregnancy, Fertilisation, Woman, Male, Safety, Literature, FDA, ICSI, Insemination, Physician, Birth control

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces topline data from its FemaSeed Localized Directional Insemination for artificial insemination pivotal trial (NCT04968847). The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility. FemaSeed, engineered to enhance fertilization by precisely delivering sperm into the fallopian tube, the site of conception, demonstrated 24% of women became pregnant after FemaSeed with severe male factor (1 million to 20 million total motile sperm count (TMSC)). In contrast, a 6.7% pregnancy rate by cycle was described in the literature for intrauterine insemination (IUI) with male factor (greater than 1 million TMSC).1 Although permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure. The poor IUI pregnancy rates for this infertility segment usually necessitates assisted reproductive approaches, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Key Points:

The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility.
“These impressive topline results for our now FDA-cleared FemaSeed, demonstrate significant progress in the treatment of infertility, while confirming its safety profile.
“The pivotal trial amassed substantial prospective data in support of the safety and efficacy of FemaSeed as a groundbreaking advancement in artificial insemination.
The pivotal trial was concluded prior to completing full enrollment due to Femasys receiving FDA clearance for FemaSeed under the 510(k) pathway in September 2023.